Loading stock data…
Halozyme Therapeutics, Inc. (HALO)
$77.18+2.22 (+2.96%)
After Hours$77.18+0.00 (+0.00%)· Last close Jun 29
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Halozyme Therapeutics, Inc. in the Healthcare sector is trading at $77.18 with a market capitalization of $8.3B. Wall Street consensus targets $83.90 (10 analysts), implying a +8.7% move over the next 12 months. The stock is currently near its 52-week high of $82.22, remaining 11.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +8.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $376.71M↓ | $451.77M↑ | $354.26M↑ | $325.72M↑ | $264.86M |
| Gross Profit | $297.47M↓ | $373.00M↑ | $299.02M↑ | $279.36M↑ | $216.46M |
| Operating Income | $184.52M↓ | $240.70M↑ | $217.92M↑ | $202.44M↑ | $141.53M |
| Net Income | $150.05M↑ | -$141.59M↓ | $175.22M↑ | $165.16M↑ | $118.09M |
Peer Comparison
JNJUNHPFE
Fundamentals
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the pate...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.50
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
158.83%
Volume
Today's trading volume
2.08M
Recent News
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?
ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2 Profitable Stocks Worth Your Attention and 1 We Question
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story
In recent days, Halozyme Therapeutics’ partner argenx reported positive new data for a therapy using Halozyme’s ENHANZE® drug delivery technology, while an analyst reaffirmed a positive rating on the company. This combination of external clinical validation and continued analyst support underscores how Halozyme’s business model is closely tied to partner success with its core platform. We’ll now examine how this fresh validation of ENHANZE® could influence Halozyme’s existing investment...
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today
Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session after an analyst reiterated a Buy rating on the stock, and a partner company, argenx, presented positive new data for a drug that utilizes Halozyme's technology.